Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Matthew Hardee

Radiation Oncology Little Rock, AR Medical Doctor

NPI 1487896973 CMS profile 547914

8901 Carti Way, Little Rock, AR 72205

Open in the dashboard

General payments

$1,946

13 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Matthew Hardee of Little Rock, AR is reported in the CMS Open Payments database as having received $1,946 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Radiation Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $957 5
2019 General $989 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Hardee
  • Radiation Oncology median
  • Middle half of Radiation Oncology
  • National median

In program year 2025, general payments to Matthew Hardee were reported at $0. Among 3,409 Radiation Oncology profiles paid that year, the median was $172 and the middle half received between $61 and $514.

Show as a table
Year Matthew Hardee Radiation Oncology median Middle half National median
2019 $989 $138 $48–$462 $163
2020 $0 $79 $26–$262 $114
2021 $0 $119 $37–$358 $132
2022 $957 $139 $43–$424 $149
2023 $0 $167 $57–$473 $160
2024 $0 $168 $56–$541 $164
2025 $0 $172 $61–$514 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Varian Medical Systems, Inc. $975 7 payments
  2. RefleXion Medical, Inc. $892 4 payments
  3. Boston Scientific Corporation $64 1 payment
  4. Siemens Medical Solutions USA, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Travel and Lodging $1,685 6 payments
  2. Food and Beverage $261 7 payments
Products named General payments · program years 2019–2022
  1. ProBeam $961 6 payments
  2. REFLEXION MEDICAL RADIOTHERAPY SYSTEM $892 4 payments
  3. SpaceOAR VUE System - 10mL $64 1 payment
  4. SOMATOM Confidence $15 1 payment
  5. TrueBeam $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

140

Median for Radiation Oncology: 65

Drug cost

$1,176

Median for Radiation Oncology: $978

Branded share of claims

8.6%

Median for Radiation Oncology: 7.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tamsulosin Hcl Generic 66 $376
Dexamethasone Generic 51 $340
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $300
Fluconazole Generic 11 $160

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,680 Part D prescribers listed as Radiation Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$483,623

Medicare's payments for the services billed

Medicare patients

402

Average age 74

Services billed

5,670

201 women, 201 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 75%
Arthritis 50%
Ischemic heart disease 33%
Diabetes 30%
COPD 23%
Depression 22%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Radiation Oncology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record